

## Statin Therapy for Patients with Cardiovascular Disease (SPC)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for statin therapy for patients with cardiovascular disease (SPC).

### What Is the Measure?

The percentage of members age 21 to 75 (males), and age 40 to 75 (females), during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and who were dispensed at least one high- or moderate-intensity statin medication and remained on the medication for at least 80% of the treatment period.

Members are identified by event or diagnosis:

- **Event:** Member was discharged from an inpatient setting with a myocardial infarction (MI) on the discharge claim, or received a coronary artery bypass graft, percutaneous coronary intervention, or any other revascularization in any setting the year prior to the measurement year
- **Diagnosis:** Members as having ischemic vascular disease (IVD) who met *at least one* of the following criteria during *both* the measurement year *and* the year prior to the measurement year:
  - At least one outpatient visit, telehealth visit, e-visit, or virtual check-in with an IVD diagnosis
  - At least one acute inpatient encounter with an IVD diagnosis without telehealth
  - At least one acute inpatient discharge with an IVD diagnosis on the discharge claim
  - Any time during the measurement year or year prior to the measurement year

### High- and Moderate-Intensity Statin Medications

#### High-Intensity Statin Medications

- Atorvastatin 40-80 mg
- Amlodipine-atorvastatin 40-80 mg
- Rosuvastatin 20-40 mg
- Simvastatin 80 mg
- Ezetimibe-simvastatin 80 mg

#### Moderate-Intensity Statin Medications:

- Atorvastatin 10-20 mg
- Amlodipine-atorvastatin 10-20 mg
- Rosuvastatin 5-10 mg
- Simvastatin 20-40 mg
- Ezetimibe-simvastatin 20-40 mg
- Pravastatin 40-80 mg
- Lovastatin 40 mg
- Fluvastatin 40-80 mg
- Pitavastatin 1-4 mg

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.

## Exclusions

- Members with the following during the measurement year or the year prior:
  - Diagnosis of pregnancy
  - In vitro fertilization
  - Dispensed at least one prescription for clomiphene
  - ESRD
  - Dialysis
  - Cirrhosis
- Members with the following conditions during the measurement year:
  - Myalgia
  - Myositis
  - Myopathy
  - Rhabdomyolysis
- Members who use hospice services or elect to use a hospice benefit during the measurement year
- Members receiving palliative care any time during the measurement year
- Members 66 years and older with advanced illness or frailty during the measurement year
- Medicare members 66 years and older living in a long-term care institution

## Best Practices

- Encourage members to use their Florida Blue ID card at the pharmacy.
- Explain the role and importance of statin therapy and discuss why they are prescribed a specific medication.
- Together, identify and resolve member-specific adherence barriers or concerns, such as the prescription's health benefits, side effects, cost, and timely refills.
- Recommend mail order and 90-day prescription of maintenance drugs. (Medicare Advantage only: Recommend 100-day prescription of maintenance drugs.)
- Statin use should always be accompanied by lifestyle modifications focused on diet and weight loss to improve a patient's lipid panel.

Content reproduced with permission from HEDIS®MY2024, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications).